| Literature DB >> 22996613 |
E C Tracy1, M J Bowman, B W Henderson, H Baumann.
Abstract
BACKGROUND: Photodynamic therapy (PDT) causes tissue damage that initiates a local inflammatory response. Post-PDT reactions are considered to assist in mobilising the immune system thereby affecting tumour recurrence. The initiating process of the PDT-dependent tissue reaction remains to be determined.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22996613 PMCID: PMC3493767 DOI: 10.1038/bjc.2012.429
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1Fibroblasts as target for irritants and alarmins. (A) Monolayers of primary cultures of N-Fb, passage 4, were treated for 15 min with the irritants or cytokines listed at the bottom. The changes in the phosphorylation of the signalling proteins indicated on the right were determined by western blotting. (B, C) N-Fb were treated for 24 h as indicated and then were exposed for 15 min to CSFE-stained neutrophils. Adherent neutrophils were imaged by CSFE-fluorescence (B, bottom panel, and C) and the change in the expression of ICAM-1 as well as the neutrophil-associated haptoglobin determined by western blotting (B, upper panels). (D) separate cultures of N-Fb were treated with the cytokines indicated at the bottom and analysed for the 15-min response to activate NFkB and p38 and for the 24-h response to induce ICAM-1 and binding of CSFE-stained neutrophils. (E) Baseline and IL-1β-inducible IL-6 production by early (P3–10) and late (P>10) passage culture of N-Fb and T-Fb were quantified by bioassay and Luminex immunobead-binding assays. Box plots compile data from 8 to 24 independent culture sets.
Figure 2Effect of PDT on lung Eps. (A–E) Replicate N-Ep cultures, passage 2, in 6-well culture dishes were incubated for 30 min with the indicated concentrations of HPPH followed by 24 h incubation in HPPH-free medium. Mitochondrially localised HPPH was determined by fluorescent microcopy (A, × 100 magnification) and quantified (C, open circles). The cultures were exposed to 665 nm light. Cells from one culture set were immediately extracted and analysed for the indicated proteins by western blotting (B). The second set of cultures was incubated for an additional 24 h. The relative level of viable cells was determined (C, closed circle). Equivalent aliquots of culture supernatant and lysate of adherent cell material were analysed by western blotting for the indicated proteins (D). Additional aliquots of conditioned media were 10-fold diluted and used to treat N-Fb in 48-well plate for 24 h (E, F). The treatment-dependent change in the cellular expression of ICAM-1 was determined by western blotting (E), binding of neutrophils (F, open squares, LUx107) and release of IL-6 activity determined on H-35 cell assay (F, closed squares). The same diluted EC-conditioned media were used to treat primary pulmonary macrophages for 24 h for determining the effect on IL-6 production (G). (H, I) Primary cultures of BEC (n=12), N-Ep (n=12), T-Ep (n=12) (H) and established Ep lines (I) were analysed for basal line and PDT-induced (50 nℳ HPPH or 100 nℳ HPPH-Gal) release of FSA during the 24-h post-PDT culture period. Box plots represent compilation of data derived from separate cell preparations representing passages 2 to 7 (H) and repeat (n=3–12) measurements on individual cultures of established lines for up to passage 90 (I).
Figure 3Kinetics of FSA and DAMP release by PDT-treated T-Ep. Adenocarcinoma-derived T-Ep, passage 4, in a 6-well plate was treated with the indicated concentrations of HPPH for 30 min followed by a 24-h culture period. After light treatment, the cultures were incubated for additional 24 h with periodic collection of CM and replacement with fresh media. Aliquots of the culture media were three-fold diluted, used to determine FSA by treating N-Fb for 24 h and determining the IL-6-dependent induction of GFP in H-35 cells (A). Equal aliquots of Ep-conditioned media were analysed for the indicated proteins by western blotting (B).
Figure 4Size separation of proteins in CM of PDT-treated T-Ep. Duplicate cultures of T-Ep, passage 3, in a 10-cm-diameter culture dish were treated either as light control or with 25 nℳ HPPH-PDT. Conditioned medium 2 and 24 h post PDT were concentrated and subjected to chromatography on a G-150 Sephadex column. Proteins in each fraction were analysed for the indicated proteins (A, upper panel), FSA in the coupled Fb-H-35 cell assay (B) and for induced neutrophil binding to the treated Fb (C). Detection of the FSA activity by chromatographed COS-1 cell-derived IL-1α is included in (B and C). The centrifuged homogenate of untreated T-Ep from one 10-cm dish was similarly size fractionated and the entire fractions were analysed for IL-1α protein by western blotting (A, lower panel). The elution positions of the molecular size markers (in kDa) are indicated at the top of the column elution profile.
Figure 5Identification of IL-1α and IL-1β as Ep-derived FSA and alarmin. Conditioned medium of control Ep cultures (Ep-PDT) and PDT-treaded Ep cultures (Ep+PDT), whole-cell homogenate of control Ep and Sephadex G-150-purified 17 kD FSA were reacted with antibodies against IL-1α or IL-1β as indicated and then tested for the ability to activate signalling (A), to enhance IL-6 that induces GFP expression in H-35 cells (B) and to increase neutrophil binding (C).
Genes inducible by Ep-derived alarmins in normal pulmonary fibroblasts
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
| 211506_s_at | Interleukin 8 | IL8 | 19 376 | 196.7 | 23 217 | 239.9 | 32 161 | 345.9 |
| 204470_at | Chemokine (C–X–C motif) ligand 1 | CXCL1 | 42 127 | 49.5 | 35 994 | 42.9 | 43 967 | 53.3 |
| 209774_x_at | Chemokine (C–X–C motif) ligand 2 | CXCL2 | 13 412 | 114.6 | 10 028 | 91.3 | 15 510 | 132.3 |
| 207850_at | Chemokine (C–X–C motif) ligand 3 | CXCL3 | 15 600 | 102.7 | 17 404 | 101.5 | 18 297 | 114.1 |
| 215101_s_at | Chemokine (C–X–C motif) ligand 5 | CXCL5 | 5704 | 126.6 | 9875 | 220.7 | 15 560 | 341.3 |
| 206336_at | Chemokine (C–X–C motif) ligand 6 | CXCL6 | 18 145 | 20.4 | 12 643 | 13.4 | 16 653 | 19.0 |
| 216598_s_at | Chemokine (C–C motif) ligand 2 | CCL2 | 34 846 | 4.3 | 34 068 | 4.4 | 31 626 | 4.0 |
| 208075_s_at | Chemokine (C–C motif) ligand 7 | CCL7 | 3903 | 14.9 | 3449 | 13.9 | 1904 | 7.2 |
| 214038_at | Chemokine (C–C motif) ligand 8 | CCL8 | 1106 | 8.6 | 1192 | 11.7 | 750 | 6.6 |
| 210133_at | Chemokine (C–C motif) ligand 11 | CCL11 | 780 | 3.4 | 1294 | 5.8 | 604 | 1.8 |
| 206407_s_at | Chemokine (C–C motif) ligand 13 | CCL13 | 352 | 2.5 | 591 | 5.1 | 303 | 2.2 |
| 205476_at | Chemokine (C–C motif) ligand 20 | CCL20 | 526 | 8.8 | 940 | 17.2 | 1680 | 30.7 |
|
| ||||||||
| 205207_at | Interleukin 6 | IL6 | 32 180 | 24.2 | 29 455 | 23.8 | 36 264 | 28.2 |
| 206924_at | Interleukin 11 | IL11 | 310 | 3.7 | 1737 | 19.4 | 1178 | 11.0 |
| 205266_at | Leukaemia inhibitory factor | LIF | 1631 | 6.0 | 1218 | 5.1 | 1111 | 4.3 |
| 206569_at | Interleukin 24 | IL24 | 850 | 7.5 | 1099 | 8.9 | 1126 | 10.0 |
| 203828_s_at | Interleukin 32 | IL32 | 2697 | 10.3 | 991 | 3.7 | 2566 | 10.1 |
| 209821_at | Interleukin 33 | IL33 | 621 | 12.2 | 851 | 17.2 | 834 | 18.0 |
|
| ||||||||
| 213921_at | Somatostatin | SST | 2176 | 7.0 | 17 922 | 67.8 | 5757 | 18.6 |
| 205767_at | Epiregulin | EREG | 786 | 8.3 | 1685 | 18.3 | 495 | 5.2 |
| 205239_at | Amphiregulin | AREG | 3204 | 4.6 | 9003 | 13.1 | 1343 | 2.0 |
| 243296_at | Pre-B-cell colony-enhancing factor 1 | PBEF1 | 2456 | 11.5 | 2777 | 12.9 | 1991 | 9.3 |
| 202410_x_at | Insulin-like growth factor 2 | IGF2 | 976 | 4.9 | 489 | 2.2 | 1123 | 5.3 |
| 204422_s_at | Fibroblast growth factor 2 (basic) | FGF2 | 9988 | 3.2 | 12 919 | 4.4 | 11 995 | 3.9 |
| 222802_at | Endothelin 1 | EDN1 | 847 | 3.2 | 1501 | 6.2 | 1130 | 3.5 |
| 205290_s_at | Bone morphogenetic protein 2 | BMP2 | 619 | 3.0 | 788 | 4.6 | 678 | 3.5 |
| 210229_s_at | Colony-stimulating factor 2 (granulocyte-macrophage) | CSF2 | 544 | 5.6 | 152 | 1.0 | 1357 | 14.7 |
| 202510_s_at | Tumour necrosis factor, alpha-induced protein 2 | TNFAIP2 | 3416 | 4.7 | 2956 | 4.7 | 3079 | 4.5 |
| 202643_s_at | Tumour necrosis factor, alpha-induced protein 3 | TNFAIP3 | 2596 | 34.3 | 1907 | 22.6 | 2775 | 32.5 |
| 206025_s_at | Tumour necrosis factor, alpha-induced protein 6 | TNFAIP6 | 18 571 | 10.7 | 22 814 | 12.9 | 19 994 | 11.1 |
| 202357_s_at | Complement factor B | CFB | 938 | 12.6 | 229 | 2.0 | 513 | 7.3 |
|
| ||||||||
| 204475_at | Matrix metallopeptidase 1 (interstitial collagenase) | MMP1 | 24 670 | 4.2 | 11 180 | 1.8 | 31 020 | 5.5 |
| 205680_at | Matrix metallopeptidase 10 (stromelysin 2) | MMP10 | 546 | 2.4 | 280 | 1.2 | 680 | 4.1 |
| 204580_at | Matrix metallopeptidase 12 (macrophage elastase) | MMP12 | 3597 | 8.9 | 331 | -1.3 | 4716 | 12.8 |
| 224942_at | Pregnancy-associated plasma protein A, pappalysin 1 | PAPPA | 6121 | 15.4 | 6342 | 16.5 | 4159 | 10.6 |
| 202902_s_at | Cathepsin S | CTSS | 916 | 5.7 | 495 | 3.1 | 1232 | 7.9 |
|
| ||||||||
| 215223_s_at | Superoxide dismutase 2, mitochondrial | SOD2 | 24 302 | 34.2 | 19 873 | 24.8 | 30 852 | 41.9 |
| 210367_s_at | Prostaglandin E synthase | PTGES | 6402 | 14.4 | 9601 | 19.5 | 7756 | 16.1 |
| 204748_at | Prostaglandin-endoperoxide synthase 2 (COX-2) | PTGS2 | 1294 | 8.5 | 1375 | 10.7 | 1433 | 10.7 |
|
| ||||||||
| 202636 _at | Intercellular adhesion molecule 1 (CD54) | ICAM1 | 1719 | 17.6 | 1907 | 11.6 | 2134 | 22.0 |
| 204273_at | Endothelin receptor-type B | EDNRB | 3095 | 8.2 | 5719 | 14.8 | 3050 | 8.7 |
| 205729_at | Oncostatin M receptor | OSMR | 1235 | 3.0 | 1579 | 3.8 | 1823 | 4.8 |
| 206172_at | Interleukin 13 receptor, alpha 2 | IL13RA2 | 8089 | 4.2 | 13 358 | 6.8 | 11 928 | 5.7 |
| 212657_s_at | Interleukin 1 receptor antagonist | IL1RN | 263 | 3.2 | 345 | 3.8 | 218 | 2.4 |
| 231779_at | Interleukin-1 receptor-associated kinase 2 | IRAK2 | 1096 | 4.3 | 1282 | 4.5 | 1249 | 4.4 |
| 218353_at | Regulator of G-protein signalling 5 | RGS5 | 825 | 6.2 | 544 | 5.4 | 781 | 5.9 |
| 223809_at | Regulator of G-protein signalling 18 | RGS18 | 388 | 4.8 | 1609 | 15.0 | 678 | 7.0 |
Abbreviations: Ep=epithelial cell; Exp=experiment; Expr.=expression.
In three independent experiments, pairs of N-Fb cultures were treated for 24 h with medium alone or containing 1/10 diluted 24-h-conditioned medium from BEC subjected to 50 nℳ HPPH-PDT. Transcripts were analysed by Affymetrix array and compared with control cultures for genes induced at least four-fold in one of the sets.
Figure 6Enhanced cell damage and release of FSA by cell surface-restricted photoreaction. A, 100 nℳ HPPH-Gal was bound to the cell surface of T-Ep, passage 3, during 30-min incubation at 4° C followed by internalisation and lysosomal deposition during a 24-h incubation at 37° C. Fluorescent micrographs of the cultures at × 100 magnification are shown. (B, C) Replicate sets T-Ep cultures in 6-well dishes were reacted with the indicated concentrations of HPPH-Gal restricted to cell surface or to be internalised. The cell-associated fluorescence was quantified (B, open circles) and the cells in all sets were treated on ice with 665 nm light. One set of cultures was immediately lysed and analysed by western blotting to the extent of STAT3 crosslinking and loss of EGFR (C). The other set was cultured for an additional 24 h to determine survival rate (B, closed circle). (D, E) Duplicate set of T-Ep, passage 5, were subjected to HPPH-Gal binding to cell surface or lysosomal accumulation at the indicated HPPH-Gal dose. The photoreaction was carried out at 0° C and the cultures were incubated for an additional 24 h. Conditioned media collected after 2 h and 24 h were analysed for FSA on N-Fb cultures (D). Equivalent aliquots of cell lysates and conditioned media were analysed by western blotting for the indicated DAMPs (E). (F, G) Replicate cultures of T-Ep in 6-well plates were subjected to high-dose mitochondrial HPPH-PDT (F) or cell-surface HPPH-Gal PDT (G) with light treatment carried out on ice. After 4-h post-PDT incubation, the adherent cells, combined with cellular debris recovered by centrifugation of CM, were homogenised. Aliquots of the cell homogenates and cell-free-CM were analysed for the amount of IL-1 activity per culture.